Education
About Us
Working with TipRanks
Follow Us
Xilio Therapeutics (XLO)
NASDAQ:XLO
XLO Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
XLO Stock 12 Month Forecast
Average Price Target
$2.00
▲(181.69% Upside)
| Highest Price Target$2.00 | Average Price Target$2.00 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$2
Buy
181.69%
Upside
Reiterated
08/15/25
TD Cowen
―
Buy
―
Reiterated
08/14/25
Promising Future for Xilio Therapeutics: Strong Financial Position and Encouraging Trial Results Support Buy RatingWe were encouraged that the response rate held up with greater patient numbers for an updated ORR of 26% (6 cPRs + 1 uPR, cORR = 22%) among 27 evaluable patients that lack liver mets vs a preliminary ORR of 27% (2 cPR + 1 uPR) among 11 patients. The emerging durability also looks promising with 6/7 PRs remaining on treatment for as long as 37 weeks (estimated median follow up time of ~9 weeks). As no new safety signals emerged, Xilio has opened up a 150mg cohort (vs 100mg from ASCO update), which should enroll about ~10 patients. An update with longer-term 100mg data and 2+ scans for the 150mg patients is expected in H1:26, likely at a medical meeting. Xilio plans to use these emerging datasets to identify a partner to push vilastobart further into clinical development.
TR | OpenAI - 4o
―
Hold
―
Reiterated
04/29/25
Morgan Stanley
$5
Buy
604.23%
Upside
Reiterated
03/11/25
Raymond James
$4
Buy
463.38%
Upside
Reiterated
02/13/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$2
Buy
181.69%
Upside
Reiterated
08/15/25
TD Cowen
―
Buy
―
Reiterated
08/14/25
Promising Future for Xilio Therapeutics: Strong Financial Position and Encouraging Trial Results Support Buy RatingWe were encouraged that the response rate held up with greater patient numbers for an updated ORR of 26% (6 cPRs + 1 uPR, cORR = 22%) among 27 evaluable patients that lack liver mets vs a preliminary ORR of 27% (2 cPR + 1 uPR) among 11 patients. The emerging durability also looks promising with 6/7 PRs remaining on treatment for as long as 37 weeks (estimated median follow up time of ~9 weeks). As no new safety signals emerged, Xilio has opened up a 150mg cohort (vs 100mg from ASCO update), which should enroll about ~10 patients. An update with longer-term 100mg data and 2+ scans for the 150mg patients is expected in H1:26, likely at a medical meeting. Xilio plans to use these emerging datasets to identify a partner to push vilastobart further into clinical development.
TR | OpenAI - 4o
―
Hold
―
Reiterated
04/29/25
Morgan Stanley
$5
Buy
604.23%
Upside
Reiterated
03/11/25
Raymond James
$4
Buy
463.38%
Upside
Reiterated
02/13/25
Best Analysts Covering Xilio Therapeutics
1 Month
xxx
Success Rate
3/8 ratings generated profit
Average Return
-19.25%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of -19.25% per trade.
3 Months
xxx
Success Rate
3/9 ratings generated profit
Average Return
-18.09%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -18.09% per trade.
1 Year
Success Rate
2/9 ratings generated profit
Average Return
-23.50%
reiterated a buy rating 6 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -23.50% per trade.
2 Years
xxx
Success Rate
2/9 ratings generated profit
Average Return
-26.03%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -26.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
XLO Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Aug 25
Strong Buy
3
3
1
0
2
Buy
2
2
2
2
3
Hold
5
2
2
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
7
5
3
5
Each month's total comprises the sum of three months' worth of ratings.
XLO Financial Forecast
XLO Stock Forecast FAQ
What is XLO’s average 12-month price target, according to analysts?
Based on analyst ratings, Xilio Therapeutics’s 12-month average price target is 2.00.
What is XLO’s upside potential, based on the analysts’ average price target?
Xilio Therapeutics has 181.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is XLO a Buy, Sell or Hold?
Xilio Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Xilio Therapeutics’s price target?
The average price target for Xilio Therapeutics is 2.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents 181.69% Increase from the current price of $0.71.
The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents 181.69% Increase from the current price of $0.71.
What do analysts say about Xilio Therapeutics?
Xilio Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of XLO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.